CagriSema: Evidence, Mechanism, Dosing & Legal Status

CagriSema is a fixed-dose combination injectable that layers two distinct metabolic mechanisms into a single once-weekly subcutaneous pen.10 Where most peptides on this site rest on animal data, CagriSema is unusual: its claims are anchored in completed, published human trials. This monograph separates the strong proof from the genuine disappointment in the narrative.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. CagriSema is investigational and not FDA-approved anywhere as of 2026; it is sold by research-chemical vendors only as "not for human use." Dosing figures are reported strictly as seen in the published clinical-trial literature for completeness. Functional/integrative framing shapes emphasis only and never overrides sourced facts. Consult a licensed clinician before any health decision.

What is CagriSema and how does it work?

CagriSema combines two peptides in one prefilled pen — cagrilintide 2.4 mg plus semaglutide 2.4 mg — both dosed once weekly subcutaneously.1910 Semaglutide mimics glucagon-like peptide-1, augmenting glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite via hypothalamic and brainstem pathways; it is the same GLP-1 analog marketed as Wegovy and Ozempic.8 Cagrilintide is a synthetic, non-selective analog of amylin — the beta-cell hormone co-secreted with insulin — acting at the amylin receptor complex (calcitonin receptor plus RAMP1/2/3) and the calcitonin receptor, slowing gastric emptying, suppressing postprandial glucagon, and reducing food intake via area-postrema and hypothalamic satiety pathways.89

The molecular design is the clever part. Cagrilintide is built on the human amylin backbone with calcitonin-inspired modifications: salt-bridge-stabilizing mutations at positions 14 and 17, proline substitutions to suppress amyloid fibril formation (native amylin is highly amyloidogenic), and an N-terminal C20 fatty-diacid moiety that confers reversible albumin binding — the same half-life-extension strategy used for semaglutide.9 This overcomes the limitation of the first-generation amylin analog pramlintide, whose ~50-minute half-life forces three daily mealtime injections.9 Cagrilintide's elimination half-life is roughly 7 days, with steady-state sustained over 6-7 days, supporting once-weekly dosing; albumin binding protects it from renal filtration and proteolysis, and semaglutide similarly has a ~5-7-day half-life.9

The rationale is dual-pathway and complementary: amylin-receptor agonism layered onto GLP-1-receptor agonism. REDEFINE 1 provided the first human evidence that these pathways are distinct enough to produce additive weight loss — CagriSema (-22.7%) exceeded semaglutide monotherapy (~-16%) and cagrilintide monotherapy (~-12%) in comparator arms.410

What is the evidence by indication?

Unlike most peptides in this encyclopedia, CagriSema is supported by multiple large, completed Phase 3 RCTs published in the New England Journal of Medicine and The Lancet. Every indication below is human evidence, graded A.

Obesity (REDEFINE 1). This 68-week, double-blind, placebo- and active-controlled Phase 3 RCT enrolled 3,417 adults with obesity or overweight plus at least one weight-related comorbidity, without type 2 diabetes (NCT05669755), and was published in NEJM in 2025.13 Mean weight loss was -22.7% versus -2.3% on placebo under the adherence estimand (difference -20.4 percentage points), and -20.4% under the treatment-policy estimand.2 Responder rates were striking: at least 20% weight loss in 60.2% of patients and at least 25% in 40.4%, with 50.7% reaching a BMI under 30.2 A body-composition substudy showed fat mass -35.7%, and significant improvements in systolic blood pressure, waist circumference, and lipids followed, with 88% of prediabetic participants returning to normoglycemia.5 The full trial record is on ClinicalTrials.gov (NCT05669755).

The "below-expectations" headline. Although -22.7% is among the highest weight loss reported for any anti-obesity drug, it fell short of the at-least-25% Novo Nordisk had guided. Only 57.3% of patients reached the top dose because the protocol permitted dose reduction for tolerability, diluting the topline.1213 The December 2024 readout cut Novo Nordisk's shares by roughly 20-26%, erasing about $72 billion in market cap.11

Type 2 diabetes (REDEFINE 2 and REIMAGINE). The 68-week REDEFINE 2 RCT (n=1,206) produced -15.7% weight loss under the adherence estimand versus -3.1% placebo, with 73.5% of patients achieving HbA1c at or below 6.5% versus 15.9% on placebo.7 The lower weight loss versus REDEFINE 1 is consistent with the known attenuation of incretin-driven weight loss in diabetic populations.6 The REIMAGINE program — multiple Phase 3 trials presented at ADA 2026 with REIMAGINE 1/2 in Lancet Diabetes & Endocrinology and REIMAGINE 3 in The Lancet — met its primary HbA1c and secondary weight endpoints across the board.18

Head-to-head vs tirzepatide (REDEFINE 4). This 84-week open-label Phase 3 RCT (n=809) was the reality check: CagriSema reached -23.0% (adherence) / -20.2% (treatment-regimen) versus tirzepatide 15 mg at -25.5% / -23.6%, and CagriSema did not meet the predefined non-inferiority criterion.141516 Longer-duration, higher-dose data from REDEFINE 11 are expected in the first half of 2027, and the cardiovascular-outcomes trial REDEFINE 3 is ongoing.17

What doses appear in the literature, and how safe is it?

Reported strictly as information, not a protocol. The Phase 3 maintenance dose is cagrilintide 2.4 mg plus semaglutide 2.4 mg once weekly subcutaneously, reached by stepwise titration over roughly 16-20 weeks to mitigate GI tolerability.10 A lower 1 mg/1 mg combination was evaluated in the REIMAGINE diabetes trials, and the standalone cagrilintide dose range in development was ~1.2-4.5 mg weekly.189 CagriSema is a finished co-formulated pen in trials, so there is no patient reconstitution; the dose-reduction allowance in REDEFINE 1 (only 57.3% reaching top dose) is itself a dosing-relevant finding, since tolerability-driven down-titration measurably lowered mean efficacy.12

The safety profile is consistent with the GLP-1 class: the great majority of adverse events were GI, mild-to-moderate, transient, and declined over time.3 In REDEFINE 1, any GI event occurred in 79.6% of CagriSema patients versus 39.9% on placebo, with nausea 55.0%, constipation 30.7%, and vomiting 26.1%; discontinuation due to adverse events was 6.0% versus 3.7%.2 A functional-medicine caveat: roughly 14% loss of lean soft tissue accompanied the fat loss in the substudy — a reminder that aggressive pharmacologic weight loss removes lean mass alongside fat, underscoring the importance of resistance training and adequate protein during therapy.2 Because no CagriSema label exists yet, class-effect risks are extrapolated from the semaglutide label: a boxed warning for thyroid C-cell tumors (contraindicated with personal or family history of medullary thyroid carcinoma or MEN2), pancreatitis, gallbladder disease, ileus, dehydration or acute kidney injury from severe GI losses, hypoglycemia when combined with insulin or sulfonylureas, and retained gastric contents under anesthesia from delayed emptying.8 Pregnancy and breastfeeding are contraindicated.

What is the FDA and WADA status in 2026?

CagriSema is not FDA-approved anywhere as of mid-2026 and is investigational worldwide.22 Novo Nordisk submitted a New Drug Application on December 18, 2025 for once-weekly CagriSema (2.4/2.4 mg) for chronic weight management in adults with obesity or overweight plus at least one comorbidity, based on REDEFINE 1 and supporting REDEFINE 2.1920 A standard 10-month review points to an expected decision around late 2026, with no public PDUFA date confirmed, and there is no publicly confirmed EMA, MHRA, or Health Canada submission.21 Because the drug is unapproved and its components are not on FDA shortage lists in this combination, there is no lawful compounding pathway for a CagriSema co-formulation, and CagriSema is not a DEA-scheduled controlled substance.22

For athletes, the anti-doping picture differs from most peptides on this site. As of 2026, semaglutide is on WADA's Monitoring Program — tracked for prevalence but not prohibited — and tirzepatide was added to monitoring for 2026; cagrilintide does not appear on the Prohibited List or Monitoring Program.23 The combination is therefore not currently banned, though athletes should verify against the current WADA list because GLP-1 misuse for body-composition manipulation is under active surveillance.24 A peptide-vendor blog claiming a 2026 move to S4 prohibition is not corroborated by official WADA or USADA sources and should be treated as unverified.

Bottom line. CagriSema pairs a deep, NEJM/Lancet-grade human evidence base with a genuine narrative of underperformance. It is the first drug to demonstrate in humans that amylin-receptor co-agonism adds to GLP-1 agonism, delivering ~20-23% weight loss in obesity — yet it undershot its own 25% guidance and failed non-inferiority to tirzepatide, so it is strong but not class-leading. It is not approved anywhere, long-term cardiovascular (REDEFINE 3) and higher-dose (REDEFINE 11, H1 2027) data are pending, and the ~14% lean-mass loss argues for muscle-preserving co-interventions. Anything sold as CagriSema or cagrilintide outside a clinical trial is unapproved, not-for-human-use research chemical of unverified quality. Regulatory facts here are current as of June 2026 and should be re-verified after the FDA decision.